Combination Antioxidant Effect of Erythropoietin and Melatonin on Renal Ischemia-Reperfusion Injury in Rats

Document Type : Original Article


1 Drug Applied Research Center, Tabriz University of Medical Sciences, Medical Faculty, Tabriz, Iran

2 Department of Physiology, Tabriz University of Medical Sciences, Tabriz, Iran

3 Department of Histology & Embryology, Tabriz University of Medical Sciences, Medical Faculty, Tabriz, Iran



Renal ischemia reperfusion (IR) contributes to the development of acute renal failure (ARF). Oxygen free radicals are considered to be principal components involved in the pathophysiological tissue alterations observed during renal IR. The purpose of this study was to investigate the effect of co-administration of melatonin (MEL) and erythropoietin (EPO), potent antioxidant and anti-inflammatory agents, on IR-induced renal injury in rats.
Materials and Methods:
Wistar albino rats were unilaterally nephrectomized and subjected to 45 min of renal pedicle occlusion followed by 24 hr reperfusion. MEL (10 mg/kg, IP) and EPO (5000 U/kg, IP) were administered prior to ischemia. After 24 hr reperfusion, following decapitation, renal samples were taken for the determination of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) levels and histological evaluation. The level of urea was measured in serum samples.
Ischemia reperfusion significantly increased urea, and MDA levels, and decreased CAT and SOD activities. Histopathological findings of the IR group confirmed that there was renal impairment in the tubular epithelium. Treatment with EPO and MEL markedly decreased urea level and increased SOD and GPx activities.
Treatment with EPO and MEL had a beneficial effect on renal IR injury. These results may show that the co-administration of MEL and EPO cannot exert more beneficial effects than either agent alone.


1. Grace PA. Ischaemia-reperfusion injury. Br J Surg. 1994; 81:637–647.
2. Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, Ward PA. Ischemia/reperfusion injury. J Surg Res. 2002; 105:248–258.
3. McCombs PR, Roberts B. Acute renal failure following resection of abdominal aortic aneurysm. Surg Gynecol Obstet. 1979; 148:175–178.
4. Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RW, Najarian JS,
et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation. 1995; 59:962–968.
5. Aronson S, Blumenthal R. Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardio-thorac Vasc Anesth. 1998; 12:567–586.
6. Masztalerz M, Wlodarczyk Z, Czuczejko J, Slupski M, Kedziora J. Superoxide anion as a marker of ischemia-reperfusion injury of the transplanted kidney. Transplant Proc. 2006; 38:46–48.
7. Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med. 2000; 109:655–678.
8. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991; 288:481–487.
9. Szabó C, Zingarelli B, O’Connor M, Salzman AL. DNA strand breakage, activation of poly-ADP ribosyl synthetase, and cellular energy depletion are involved in the cytotoxicity in macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA. 1996; 93:1753–1758.
10. MacMillan-Crow LA, Crow J, Kerby J, Beckman JS, Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA.1996; 93:11853–11858.
11. Yamakura F, Taka H, Fujimura T, Murayama K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem. 1998; 273:14085–14089.
12. Das DK, Maulik N. Antioxidant effectiveness in ischemia reperfusion tissue injury. Methods Enzymol. 1994; 233:601–610.
13. Ikeda K, Negishi H, Yamori Y. Antioxidant nutrients and hypoxia/ischemia brain injury in rodents. Toxicology. 2003; 189:55–61.
14. Rakotovao A, Berthonneche C, Guiraud A, de Lorgeril M, Salen P, de Leiris J,
et al. Ethanol, wine, and experimental cardioprotection in ischemia/reperfusion: role of the prooxidant/antioxidant balance. Antioxid Redox Signal. 2004; 6:431–438.
15. Glantzounis GK, Salacinski HJ, Yang W, Davidson BR, Seifalian AM. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review. Liver Transpl. 2005; 11:1031–1047.
16. Singh I, Gulati S, Orak JK, Singh AK. Expression of antioxidant enzymes in rat kidney during ischemia-reperfusion injury. Mol Cell Biochem. 1993; 125: 97–104.
17. Davies SJ, Reichardt-Pascal SY, Vaughan D, Russell GI. Differential effect of ischaemia-reperfusion injury on anti-oxidant enzyme activity in the rat kidney. Exp Nephrol. 1995; 3:348–354.
18. Conti M, Eschwege P, Ahmed M, Paradis V, Droupy S, Loric S,
et al. Antioxidant enzymatic activities and renal warm ischemia: correlation with the duration of ischemia. Transplant Proc. 2000; 32:2740–2741.
19. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury. Naunyn Schmiedebergs. Arch Pharmacol.2007; 376:1–43.
20. Kacmaz A, Polat A, User Y, Tilki M, Ozkan S, Sener G. Octreotide improves reperfusion-induced oxidative injury in acute abdominal hypertension in rats. J Gastrointest Surg. 2004; 8:113-119.
21. Benjamin B, Ebert L, Bunn HF. Regulation of erythropoietin gene. Blood. 1999; 94: 1864–1877.
22. Siren AL, Ehrenreich H. Erythropoietin – a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001; 251: 179–184.
Erythropoietin and Melatonin on Renal IR Injury Ahmadiasl et al
Iran J Basic Med Sci, Vol. 16, No. 12, Dec 2013
23. Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res. 2004; 1000: 19–31.
24. Westenfelder C, Biddle DL, Baranowski RL. Human, rat and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999; 55: 808–820.
25. Calo LA, Bertipaglia L, Pagnin E. Antioxidants, carnitine and erythropoietin. G Ital Nefrol. 2006; 34: 547–550.
26. Aluclu MU, Acar A, Guzel A, Bahceci S, Yaldiz M. Evaluation of erythropoietin effects on cerebral ischemia in rats. Neuro Endocrinol Lett. 2007; 28: 170–174.
27. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006; 48:2161–2167.
28. Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M,
et al. Recombinant human erythropoietin protects the liver from hepatic ischemia reperfusion injury in the rat. Transpl Int. 2006; 19:919–926.
29. Wu H, Ren B, Zhu J, Dong G, Xu B, Wang C,
et al. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg. 2006; 29:902–907.
30. Plotnikov EY, Chupyrkina AA, Jankauskas SS, Pevzner IB, Silachev DN, Skulachev VP,
et al. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys, Acta. 2011; 1812: 77–86.
31. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC,
et al. Melatonin: a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann NY Acad Sci.1994; 17: 419–420.
32. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci. 2000; 7: 444–458.
33. Reiter RJ, Tan DX, Pilar Terron M, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol.2007; 54: 1–9.
34. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J.1993; 1: 57–60.
35. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005; 27:189– 200.
36. Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C,
et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine(AMK), in macrophages. J Neuroimmunol. 2005; 165: 139–149.
37. Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005; 39: 215–216.
38. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V,
et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004; 36:1–9.
39. Maldonado MD, Murillo-Cabezas F, Terron MP, Flores LJ, Tan DX, Manchester LC,
et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res. 2007; 42:1–11.
40. Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging: relation to melatonin. Ann NY Acad Sci. 1998; 854: 410–424.
41. Kaya H, Sezik M, Ozkaya O, Dittrich R, Siebzehnrubl E, Wildt L. Lipid peroxidation at various estradiol concentrations in human circulation during ovarian stimulation with exogenous gonadotropins. Horm Metab Res. 2004; 36:693–695.
42. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med.1967; 70:158–169.
43. Paoletti F, Aldinucci D, Mocali A, Caparrini A. A sensitive spectrophotometric method for the determination of superoxide dismutase activity in tissue extracts. Anal Biochem.1986; 154:536-541.
44. Aebi Y. Catalase
in vitro. Methods Enzymol. 1984; 105:121–126.
45. Carden DL, Granger DN. Pathophysiology of ischemia reperfusion injury. J Pathol. 2000; 190:255-266.
46. Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, et al. Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol. 2001; 281:F948-57.
47. Sekhon CS, Sekhon BK, Singh I, Orak JK, Singh AK. Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. J Nephrol.2003; 16:63-74.
48. Kevin LG, Novalija E, Stowe DF. Reactive oxygen species as mediators of cardiac injury and protection: The relevance to anesthesia practice. Anesth Analg. 2005; 101:1275-1287.
49. McCord JM. The evaluation of free radicals and oxidative stress. Am J Med. 2000; 108:652-659.
50. Hagiwara S, Koga H, Iwasaka H, Kudo K, Hasegawa A, Kusaka J,
et al. ETS-GS, a New Antioxidant, Ameliorates Renal Ischemia-Reperfusion Injury in a Rodent Model. J Surg Res. 2011; 171:226-233.
51. Eschwege P, Paradis V, Conti M, Holstege A, Richet F, Detève J, et al. In situ detection of lipid peroxidation by-products as markers of renal ischemia injuries in rat kidneys. J Urol. 1999; 162:553-557.
52. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N,
et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol. 2000; 401:349-356.
53. Ates E, Yalcin AU, Yılmaz S, Koken T, Tokyol C. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg. 2005;75:1100-1115.
54. Reiter RJ, OH C-S, Fujimori O. Melatonin: its intracellular and genomic actions. Trends Endocrinol Metab. 1996; 7:22-27.
55. Atahan E, Ergun Y, Kurutas EB, Cetinus E, Guney Ergun U. Ischemia-reperfusion injury in rat skeletal muscle is attenuated by zinc aspartate. J Surg Res. 2007; 137:109-116.
56. Onem G, Aral E, Enli Y, Oguz EO, Coskun E, Aybek H,
et al. Neuroprotective effects of L-carnitine and vitamin
Ahmadiasl et al Erythropoietin and Melatonin on Renal IR Injury
Iran J Basic Med Sci, Vol. 16, No. 12, Dec 2013
E alone or in combination against ischemia-reperfusion injury in rats. J Surg Res. 2006; 131:124-130.
57. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M,
et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998; 95:4635–40.
58. Li Z, Nickkholgh A,Yi X, Bruns H, Gross ML, Hoffmann K,
et al. Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-kB and apoptosis after experimental kidney transplantation. J Pineal Res. 2009; 46:365–372.
59. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulating effect of melatonin on antioxidative enzymes. J Pineal Res. 2005; 39:99–104.
60. Tan DX, Manchester LC, Burkhardt S, Sainz RM, Mayo JC, Kohen R,
et al. N1-acetyl- N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001; 15:2294–2296.
61. Guenther AL, Schmidt SI, Laatsch H, Fotso S, Ness H, Ressmeyer AR,
et al. Reactions of the melatonin metabolite AMK (N1-acetyl-5-methoxykynuramine) with reactive nitrogen species: formation of novel compounds, 3-acetamidomethyl-6-methoxycinnoli none and 3- nitro-AMK. J Pineal Res. 2005; 39:251–260.
62. Tan DX, Manchester LC, Terran MR. The molecule,
many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res. 2007; 42: 28–42.
63. Paller MS. Pathophysiologic mechanisms of acute renal failure. In: Mechanisms of Injury in Renal Disease and Toxicity. Goldstein RS. ed. Ann Arbor. CRC Press. 1994; pp. 3–13.
64. Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O,
et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant. 2006; 21: 330–336.
65. Ramírez-Rodríguez G, Meza I, Hernández ME, Castillo A, Benítez-King G. Melatonin induced cyclic modulation of vectorial water transport in kidney-derived MDCK cells. Kidney Int. 2003; 63:1356–1364.
66. Burg MB. Molecular basis of osmotic regulation. Am J Physiol. 1995; 268:F983–996.
67. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M,
et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004; 15:2115-2124.
68. Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y, Yegen BC. The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J. Pineal Res. 2002; 32:120–126